Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
Metastatic breast carcinoma to the ovary is sometimes difficult to differentiate from primary ovarian carcinoma. This problem is often encountered in breast carcinoma patients who develop adnexal masses. ER and PR can be positive in a high percentage of breast and ovarian carcinomas, and therefore cannot be used in the differential diagnosis of these entities. WT1 and CA125 have been identified as possible markers for ovarian cancer. However, no studies have been done that specifically compare the immunophenotype of breast carcinoma metastatic to ovary with that of primary ovarian cancer. Thirty-nine cases of metastatic breast carcinoma to the ovary, 36 primary breast carcinomas, and 42 primary ovarian carcinomas were examined immunohistochemically for the expression of WT1, CA125, carcinoembryonic antigen, MUC2, MUC1, and GCDFP. The percentage of cells stained and the intensity of staining were recorded. Thirty-two ovarian carcinomas (76%) were positive for WT1, including 31 of 33 (94%) serous carcinomas. Most of them had strong and diffuse staining. None of the breast cancers either primary or metastatic to the ovary expressed WT1. Thirty-eight (90%) ovarian carcinomas were positive for CA125, most of them with strong and diffuse staining. Most breast carcinomas were negative for CA125, with only 6 (16%) of the primary ones and 5 (12%) of the metastatic showing weak and focal positivity. All ovarian carcinomas were negative for GCDFP. Five primary breast cancers (14%) and 17 (43%) metastatic to the ovary were positive for GCDFP. Nine (21%) ovarian carcinomas, 8 (22%) primary breast carcinomas, and 13 (33%) metastatic to the ovary were positive for carcinoembryonic antigen. Almost all tumors examined were positive for MUC1 (100% ovarian carcinomas, 100% primary breast carcinomas, and 95% metastatic breast carcinomas to ovary). MUC2 was positive in 10 (24%) ovarian carcinomas, 3 (8%) primary breast cancers, and 12 (30%) metastases to the ovary. The presence of immunoreactivity for WT1 and CA125 in a carcinoma involving ovary strongly favors a primary lesion. Most ovarian carcinomas are positive for both markers, whereas the majority of metastatic breast carcinomas to the ovary are negative. GCDFP can be complementary in this differential diagnosis.
Tornos
Carmen
C
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Soslow
Robert
R
Chen
Shirley
S
Akram
Muzaffar
M
Hummer
Amanda J
AJ
Abu-Rustum
Nadeen
N
Norton
Larry
L
Tan
Lee K
LK
D000941:Antigens / Q000096:biosynthesis; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D018394:CA-125 Antigen / Q000096:biosynthesis*; D002272:Carcinoembryonic Antigen / Q000096:biosynthesis; D002352:Carrier Proteins / Q000096:biosynthesis*; D003937:Diagnosis, Differential; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis*; D006801:Humans; D026901:Membrane Transport Proteins; D018396:Mucin-1; D055262:Mucin-2; D009077:Mucins / Q000096:biosynthesis; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D025721:WT1 Proteins / Q000096:biosynthesis*
D000941:Antigens; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D002272:Carcinoembryonic Antigen; D002352:Carrier Proteins; D006023:Glycoproteins; C060192:MUC1 protein, human; C524625:MUC2 protein, human; D026901:Membrane Transport Proteins; D018396:Mucin-1; D055262:Mucin-2; D009077:Mucins; C488892:PIP protein, human; D025721:WT1 Proteins